Salute e Benessere
SKAN Research Trust and Quadram Institute Bioscience to Develop Novel Microbial Therapies
The joint study titled the will be led by Quadram Principal Investigator, Prof. Mark Webber and SKAN's Deputy Director, Dr Yogesh Shouche . The project is part of a larger between the two organizations that have ongoing international collaborations focused on gut health and developing gut microbial therapies to alleviate ageing and neurological diseases like Parkinsons.
An important aspect of the international collaboration is sharing the latest technologies in the study of the gut microbiome to augment Indian research capabilities. As part of this study, SKAN researchers will be trained on the TraDIS Xpress platform at the Quadram Institute in Norwich Research Park. This will facilitate the generation of data from large Indian cohorts that will aid in the development of India -specific therapies. Such data generation is also expected to hasten the TraDIS-Xpress platform's development and amplify its applications' scope.
said,
said,
, said,
said,
SKAN is a Bengaluru-based not-for-profit medical research trust that leverages transformational technologies to develop new therapies for ageing and neurological ailments, cardiovascular diseases, diabetes remission and lifestyle related disorders. SKAN applies its expertise in gut microbiome, genomics, stem cells, molecular biology, biomarkers, immunotherapies, nutrition, and alternate therapies to uncover kinder and gentler treatment protocols for ailments. Bioinformatics at SKAN vigorously pursues cutting edge, artificial intelligence, machine learning and other advanced technologies to predict, pre-empt, diagnose, treat, and facilitate remission of medical disorders. The Mission statement of SKAN is " ".
contactus@skanrt.in
Talent@SKANrt.in
Quadram Institute Bioscience is a UK national science capability, and its mission is to deliver healthier lives through innovation in gut health, microbiology and food and its vision is focused on understanding how food and microbes interact to promote health and prevent disease. Interconnected research themes at the Quadram Institute on the Norwich Research Park, UK, deliver a pipeline of research in plants, microbiology, food, and health: microbes and food safety; the gut microbiome; and food innovation.
TraDIS-Xpress (transposon-directed insertion-site sequencing) is a high-resolution whole-genome assay that identifies which genes are likely to affect bacterial fitness in any given condition. This uses extremely dense, highly saturated mutant libraries to identify fitness differences at base pair resolution.
TraDIS-Xpress improves upon conventional transposon mutagenesis approaches through the use of outward-facing promoters. This allows the investigation of how gene expression, as well as gene deletion, affects bacterial fitness under a given growth condition. Additionally, it allows the investigation of essential genes that cannot be inactivated and therefore cannot be assayed by other approaches.
Photo: https://mma.prnewswire.com/media/2437959/Novel_Microbial_Therapies.jpg
Logo: https://mma.prnewswire.com/media/2082007/4257624/SKAN_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/skan-research-trust-and-quadram-institute-bioscience-to-develop-novel-microbial-therapies-302172054.html